{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:33:08Z","timestamp":1789669988593,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.3816\/cbc.2000.n.003","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:42Z","timestamp":1221080682000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Treatment of Metastatic Bone Disease in Breast Cancer: Bisphosphonates"],"prefix":"10.3816","volume":"1","author":[{"given":"Ingo J.","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich-Franz","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Bastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2000.n.003_bib1","series-title":"Skeletal Metastases","author":"Galasko","year":"1986"},{"key":"10.3816\/CBC.2000.n.003_bib2","first-page":"5","article-title":"Cancer statistics, 1997","volume":"47","author":"Parker","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2000.n.003_bib3","series-title":"Statistisches Jahrbuch der Bundesrepublik Deutschland 1995 (Gesundheitswesen)","author":"Statistisches Bundesamt","year":"1995"},{"key":"10.3816\/CBC.2000.n.003_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00000658-194007000-00016","article-title":"The function of the vertebral veins and their role in the spread of metastases","volume":"112","author":"Batson","year":"1940","journal-title":"Ann Surg"},{"key":"10.3816\/CBC.2000.n.003_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/1097-0142(195105)4:3<610::AID-CNCR2820040312>3.0.CO;2-Q","article-title":"The role of the vertebral venous system in the metastasis of cancer to the spinal column: experiments with tumor cell suspensions in rats and rabbits","volume":"4","author":"Coman","year":"1951","journal-title":"Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1126\/science.569363","article-title":"Chemotactic response of tumor cells to products of resorbing bone","volume":"203","author":"Orr","year":"1979","journal-title":"Science"},{"key":"10.3816\/CBC.2000.n.003_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/275132a0","article-title":"Resorbing bone is chemotactic for monocytes","volume":"275","author":"Mundy","year":"1978","journal-title":"Nature"},{"key":"10.3816\/CBC.2000.n.003_bib8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/88.22.1652","article-title":"Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status","volume":"88","author":"Diel","year":"1996","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"10.3816\/CBC.2000.n.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanism of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"key":"10.3816\/CBC.2000.n.003_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/263507a0","article-title":"Mechanisms of bone destruction in the development of skeletal metastases","volume":"263","author":"Galasko","year":"1976","journal-title":"Nature"},{"key":"10.3816\/CBC.2000.n.003_bib11","series-title":"Metastatic Bone Disease. Fundamental and Clinical Aspects","first-page":"221","article-title":"Morphological findings in bone metastasis, tumorosteopathy and antiosteolytic therapy","author":"Krempien","year":"1994"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.003_bib12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1608::AID-CNCR11>3.0.CO;2-3","article-title":"Mechanisms and management of bone pain","volume":"80","author":"Payne","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and efficacy of therapy related to the first site of recurrence","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2000.n.003_bib14","series-title":"Hypercalcemia of Malignancy","author":"Raue","year":"1994"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.003_bib15","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1564::AID-CNCR6>3.0.CO;2-K","article-title":"Parathyroid hormone-related protein and hypercalcemia","volume":"80","author":"Rankin","year":"1997","journal-title":"Cancer"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.003_bib16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","article-title":"Parathyroid hormone-related protein and bone metastases","volume":"80","author":"Guise","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0959-8049(05)80127-3","article-title":"Parathyroid hormone related protein and skeletal morbidity in breast cancer","volume":"28","author":"Bundred","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib18","first-page":"7710","article-title":"Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer","volume":"50","author":"Southby","year":"1990","journal-title":"Cancer Res"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.003_bib19","article-title":"Immunoreactive detection of parathroid hormone related protein (PTHrP) in primary breast cancers is a good prognostic factor for subsequent bone metastases","volume":"33","author":"Gollan","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: Pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib21","first-page":"63","article-title":"Osteopathy due to methotrexate","volume":"3","author":"Koller","year":"1976","journal-title":"\u00d6sterr Kneipp Mag"},{"key":"10.3816\/CBC.2000.n.003_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1040-8428(88)80009-X","article-title":"Effects of cancer treatment on the reproductive system","volume":"8","author":"Gradishar","year":"1988","journal-title":"CRC Crit Rev Oncol Hematol"},{"key":"10.3816\/CBC.2000.n.003_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.3816\/CBC.2000.n.003_bib26","series-title":"Bisphosphonates in Bone Disease. From the laboratory to the patient","author":"Fleisch","year":"1997"},{"key":"10.3816\/CBC.2000.n.003_bib27","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CBC.2000.n.003_bib28","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2000.n.003_bib29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposomeencapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2000.n.003_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2000.n.003_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jbmr.5650111015","article-title":"Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism","volume":"11","author":"Rogers","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2000.n.003_bib32","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"Van der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CBC.2000.n.003_bib33","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.3816\/CBC.2000.n.003_bib34","doi-asserted-by":"crossref","first-page":"101S","DOI":"10.1016\/8756-3282(95)00194-I","article-title":"Bone and Cancer: pathophysiology and treatment of metastases","volume":"17","author":"Kanis","year":"1995","journal-title":"Bone"},{"key":"10.3816\/CBC.2000.n.003_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","article-title":"Use of bisphosphonates in cancer patients","volume":"22","author":"Body","year":"1996","journal-title":"Cancer Treat Rev"},{"issue":"suppl 11","key":"10.3816\/CBC.2000.n.003_bib36","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/1097-0142(19931201)72:11+<3443::AID-CNCR2820721611>3.0.CO;2-3","article-title":"New bisphosphonates in the treatment of bone metastases","volume":"72","author":"Averbuch","year":"1993","journal-title":"Cancer"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.003_bib37","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.0.CO;2-Y","article-title":"Bisphosphonates and breast carcinoma","volume":"80","author":"Lipton","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","article-title":"Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review","volume":"16","author":"Bloomfield","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2125.1992.tb04101.x","article-title":"Medical management of hypercalcaemia","volume":"34","author":"Ralston","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CBC.2000.n.003_bib40","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00001622-199208000-00005","article-title":"Bone metastases and tumor-induced hypercalcemia","volume":"4","author":"Body","year":"1992","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","article-title":"A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy","volume":"72","author":"Purohit","year":"1995","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.annonc.a058841","article-title":"Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type","volume":"5","author":"Body","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1996.14.1.268","article-title":"Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy","volume":"14","author":"Pecherstorfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/bjc.1997.48","article-title":"Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia","volume":"75","author":"Ralston","year":"1997","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(83)90958-0","article-title":"Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton","volume":"74","author":"Siris","year":"1983","journal-title":"Am J Med"},{"key":"10.3816\/CBC.2000.n.003_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"key":"10.3816\/CBC.2000.n.003_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"van Holten-Verzantvoort","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib49","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during longterm bisphosphonate (APD) treatment","volume":"2","author":"van Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"key":"10.3816\/CBC.2000.n.003_bib50","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib51","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and bone metastases. Protocol 19 Aredia Breast Cancer Cooperative Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2000.n.003_bib52","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib53","first-page":"575a","article-title":"Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone","volume":"18","author":"Body","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2000.n.003_bib54","article-title":"Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate","volume":"35","author":"Diel","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib55","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antiestogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2000.n.003_bib56","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes a rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib58","first-page":"111","article-title":"Clodronate for osteolytic metastases due to breast cancer","volume":"42","author":"Elomaa","year":"1988","journal-title":"Biomed Pharmacother"},{"key":"10.3816\/CBC.2000.n.003_bib59","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2000.n.003_bib60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CBC.2000.n.003_bib62","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2000.n.003_bib64","first-page":"128a","article-title":"No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients","volume":"18","author":"Saarto","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2000.n.003_bib65","first-page":"123a","article-title":"Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer","volume":"17","author":"Powles","year":"1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:19Z","timestamp":1761512779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911701045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["S1526820911701045"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2000.n.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2000,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Metastatic Bone Disease in Breast Cancer: Bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2000.n.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}